Disc Medicine
Develops treatments for patients with serious hematologic diseases.
Company facts
- Founded
- 2017
- Employees
- 155
- Headquarters
- United States
- CEO
- John Quisel
- Type
- Public
- Listed
- NASDAQ: IRON
About
Disc Medicine is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. The company is building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. With a focused approach on hematology, Disc Medicine is advancing multiple clinical programs targeting rare genetic disorders and common anemias of chronic disease. Their pipeline includes Bitopertin, an orally administered GlyT1 inhibitor for erythropoietic protoporphyrias; DISC-0974, an anti-HJV monoclonal antibody for hepcidin suppression in anemia; and DISC-3405, an anti-TMPRSS6 antibody for hepcidin induction. The company operates from its headquarters in Watertown, Massachusetts, and is publicly traded on NASDAQ under the ticker IRON.